In the second quarter of 2026, Pfizer reported USD 15.03 billion in revenue and a GAAP loss per share of USD 0.04. Its ...

Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters ...

Pfizer is rated a Buy with new and acquired products generated $3.2B in Q2, growing 18% YoY and $13B annualized run-rate.

Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Pfizer Inc. (NYSE: PFE) closed at $28.40 on October 12. The stock has returned almost 4% during the last six months, compared ...

Pfizer (PFE) ended the recent trading session at $28.10, demonstrating a -1.47% change from the preceding day's closing price ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Shares of global pharmaceutical company Pfizer (NYSE: ...

Pfizer faces some major LoE headwinds, but the stock is cheap and offers a large dividend, offering a solid total return potential. Click to read more on PFE.

Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs ...